Coastal Financial Corporation (CCB)

Sage Therapeutics Stock Forecast

Stock Price Forecast

The 3 analysts that cover Sage Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $105, which forecasts a 5.54% increase in the stock price over the next year. The lowest target is $100 and the highest is $115.

Price Target: $105 (+5.54%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$100	$105	$100	$115
Change	+0.51%	+5.54%	+0.51%	+15.59%

Analyst Ratings

The average analyst rating for Sage Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	1	1	1	1	1	1
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Timothy Switzer Keefe, Bruyette & Woods	Keefe, Bruyette & Woods	Buy Maintains $110 → $115	Buy	Maintains	$110 → $115	+15.59%	Jul 11, 2025
Timothy Switzer Keefe, Bruyette & Woods	Keefe, Bruyette & Woods	Buy Maintains $114 → $110	Buy	Maintains	$114 → $110	+10.56%	Apr 30, 2025
David Feaster Raymond James	Raymond James	Strong Buy Maintains $105 → $100	Strong Buy	Maintains	$105 → $100	+0.51%	Apr 30, 2025
David Feaster Raymond James	Raymond James	Strong Buy Maintains $100 → $105	Strong Buy	Maintains	$100 → $105	+5.54%	Apr 2, 2025
Andrew Terrell Stephens & Co.	Stephens & Co.	Buy Reiterates $100	Buy	Reiterates	$100	+0.51%	Mar 18, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

634.90M

Increased by 109.11%

from 303.63M

Revenue Next Year

865.39M

Increased by 36.30%

from 634.90M

EPS This Year

3.93

Increased by 20.47%

from 3.26

EPS Next Year

6.94

Increased by 76.58%

from 3.93

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	57.26M	97.64M	215.65M	251.71M	303.63M	634.90M	865.39M
Revenue Growth	20.13%	70.52%	120.87%	16.72%	20.63%	109.11%	36.30%
EPS	1.24	2.16	3.01	3.27	3.26	3.93	6.94
EPS Growth	14.82%	74.19%	39.35%	8.64%	-0.31%	20.47%	76.58%
Forward PE	-	-	-	-	-	25.33	14.35
No. Analysts	-	-	-	-	-	5	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	697.9M	1.0B
Avg	634.9M	865.4M
Low	595.9M	779.5M

Revenue Growth

Revenue Growth	2025	2026
High	129.9%	61.8%
Avg	109.1%	36.3%
Low	96.3%	22.8%

EPS Forecast

EPS	2025	2026
High	4.50	8.25
Avg	3.93	6.94
Low	3.28	5.45

EPS Growth

EPS Growth	2025	2026
High	38.2%	110.1%
Avg	20.5%	76.6%
Low	0.5%	38.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.